-
Mashup Score: 16
Matteo Lambertini, MD, PhD, Ann H Partridge, MD, MPH; Cyclophosphamide-free Adjuvant Chemotherapy for the Potential Prevention of Premature Ovarian Insufficienc
Source: OUP AcademicCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1Cyclophosphamide and Vinorelbine Activate Stem-Like CD8+ T Cells and Improve Anti-PD-1 Efficacy in Triple-Negative Breast Cancer - 3 year(s) ago
Checkpoint inhibitors (CI) instigate anticancer immunity in many neoplastic diseases, albeit only in a fraction of patients. The clinical success of cyclophosphamide (C)-based haploidentical stem-cell transplants indicates that this drug may re-orchestrate the immune system. Using models of triple-negative breast cancer (TNBC) with different intratumoral immune contexture, we demonstrate that a…
Source: Cancer ResearchCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#Cyclophosphamide and #vinorelbine increases anti-PD-1 efficacy in breast cancer by activating antigen presenting cells and abrogating local and metastatic tumor growth by a T-cell-related effect. @fakechek1 https://t.co/smM6OSEYYN https://t.co/M3gNURmdXz
-
-
Mashup Score: 1Cyclophosphamide and vinorelbine activate stem-like CD8+ T cells and improve anti-PD-1 efficacy in triple-negative breast cancer - 3 year(s) ago
Checkpoint inhibitors (CI) instigate anticancer immunity in many neoplastic diseases, albeit only in a fraction of patients. The clinical success of cyclophosphamide (C)-based haploidentical stem-cell transplants indicates that this drug may re-orchestrate the immune system. Using models of triple-negative breast cancer (TNBC) with different intratumoral immune contexture, we demonstrate that a…
Source: Cancer ResearchCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#Cyclophosphamide and #vinorelbine increases anti-PD-1 efficacy in breast cancer by activating antigen presenting cells and abrogating local and metastatic tumor growth by a T-cell-related effect. @fakechek1 https://t.co/qDF7ZyBdlw https://t.co/KYinfOcjeG
-
-
Mashup Score: 4
In patients with early-stage TNBC, neoadjuvant treatment with atezolizumab in combination with nab-paclitaxel and anthracycline-based chemotherapy significantly improved pathological complete response rates with an acceptable safety profile.
Source: The LancetCategories: Hem/Oncs, Latest HeadlinesTweet-
Presented at #ESMO20 and published in the @TheLancet results from #IMpassion031 showing benefit of adding #atezolizumab to #nabPaclitaxel followed by #doxorubicin + #cyclophosphamide as neoadjuvant therapy for early #TripleNegative #breastcancer @OncoAlert https://t.co/478ad6gX6B https://t.co/daq6HNOTBE
-
-
Mashup Score: 7Outcome of pulse oral cyclophosphamide therapy in scleroderma interstitial lung disease - 4 year(s) ago
Standard regimens for scleroderma interstitial lung diseases (SSc-ILDs) are pulse intravenous (IV) and oral daily cyclophosphamide (CYC). However, IV CYC has limited access to diffuse cutaneous SSc, and oral daily CYC is associated with febrile neutropenia and hemorrhagic cystitis. Pulse oral CYC regimen has never been studied. To determine the effectiveness of pulse oral CYC therapy in SSc-ILDs,…
Source: Clinical RheumatologyCategories: Latest Headlines, RheumatologyTweet-
Pulse oral #cyclophosphamide therapy in #Scleroderma #InterstitialLungDisease: 📌3/4 of SSc-ILDs patients - good response with a few serious side effects. 📌Pulse oral CYC therapy is effective for #SSc #ILDs in case of difficult IV access. 👉📎 https://t.co/VBngIH0wK0 https://t.co/fo8JvG6x3X
-
-
Mashup Score: 1
R-CHOP combined with rituximab and high-dose methotrexate plus intrathecal chemotherapy is a safe and active treatment for patients with IVLBCL without apparent CNS involvement at diagnosis, and this regimen warrants future investigation.
Source: The Lancet OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
ICYMI: phase 2 trial of #rituximab, #cyclophosphamide, #doxorubicin, #vincristine & #prednisolone plus high-dose #methotrexate plus #intrathecal #chemotherapy for newly diagnosed intravascular large B-cell #lymphoma—the PRIMEUR-IVL study #lymsm https://t.co/sG2j5udI31
-
Excited to see my name in @JNCI_Now next to the super @YoungStrongDFCI commenting on a phase III trial investigating #cyclophosphamide-free adjuvant #chemotherapy in young #BreastCancer patients to reduce #gonadotoxicity @OncoAlert #bcsm #oncofertility https://t.co/CCvXh5lXsq